[Antithrombotic treatment of acute coronary syndrome].
After we have become aware that arteriosclerosis provokes thrombotic and thromboembolic process, which is the most common cause of occlusion of coronary arteries, in the past 30 years significant improvements have been made in antithrombotic treatment of acute coronary syndrome. Antithrombotic therapy of acute coronary syndrome has been explored in few directions. These are thrombolytic multidrug therapy, anticoagulant therapy with nonfractional and low molecular heparin, therapy with glycoprotein IIb/IIIa receptor antagonists and antiaggregation therapy with acetylsalicylic acid and tienopyrid. Research results and clinical experience point to a conclusion that antithrombotic therapy is the cornerstone in the mariagement of acute coronary syndrome. In this paper, results of major studies and main antithrombotic treatment guidelines in acute coronary syndrome accepted by international professional associations are presented.
Bergovec
Mijo
M
Zavod za bolesti srca i krvnih zila, Interna klinika Medicinskog fakulteta Sveucilista u Zagrebu, Klinicka bolnica Dubrava, Avenija G. Suska 6 10000 Zagreb, Hrvatska. mijo.bergovec@usa.net
D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin